Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Giant Cell Tumor of Tendon Sheath 3Synovitis, Pigmented Villonodular 2Neoplasm Metastasis 2Melanoma 2Gastrointestinal Stromal Tumors 2Stage I Prostate Adenocarcinoma 1Solid Tumors 1Solid Tumor 1Recurrence 1Pancreatic Neoplasms 1Neoplasms 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Glioblastoma 1Colorectal Neoplasms 1Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms × pexidartinib × Clear all
NCT01596751 2020-07-17

Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

University of California, San Francisco

Phase 1/2 Completed
67 enrolled 19 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡